$DLB

Couling John D sold $460K of DLB

Couling John D (SVP, Entertainment) sold 7,667 shares of Dolby Laboratories, Inc. (DLB) at an average of $60.00 ($59.03–$60.11, $0.46M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Couling John D
Published Aug 5, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DLB
Neutral
high confidence
Mentioned
$DLB
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DLBNeutralLow
01

Why it matters

The only new information is the disclosed sale size, execution dates, average prices, and post-transaction share count; it does not include any new company performance or outlook details.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing absent additional catalysts.

03

What to watch

The filing does not state whether other insiders or the company also made concurrent purchases, nor does it provide context on compensation timing or tax-related selling beyond the 10b5-1 designation.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-05, covering sales executed 2026-08-03.

Background

The article is a SEC Form 4 insider transaction disclosure for Dolby Laboratories, Inc. (DLB) by Couling John D, SVP, Entertainment.

Company-level read

Ticker impact

$DLBNeutralHigh confidence
Context

Dolby Laboratories SVP sold $460,003.89 of DLB shares via a 10b5-1 plan on 2026-08-03, disclosing post-sale holdings of 118,727 shares.

Expected impact

Likely limited near-term price impact; any effect would be modest and short-lived unless paired with other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and it does not include new operational, financial, or regulatory information.

Market effects

No clear sector read-through because the disclosure is an individual insider sale without accompanying company guidance or product/regulatory updates.

None indicated; this is a US-listed issuer insider transaction.

None indicated; no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so the market should not over-interpret it.

Key entities

  • Dolby Laboratories, Inc.

    US-listed company whose shares were sold by an insider under a 10b5-1 plan.

  • Couling John D

    SVP, Entertainment who executed open-market sales totaling $460,003.89.

Related articles

$DLBMed

Dolby Laboratories, Inc. Q3 2026 Earnings Call Summary

Dolby Laboratories’ Q3 2026 earnings call said it is shifting toward content platforms and usage-based revenue, targeting 10% of total revenue from partners by FY2028. Management cited traction for its Video Distribution Program, including Meta and Alibaba deals, and a China-first automotive strategy. Q4 guidance calls for 23% YoY revenue growth, with a $4M restructuring charge and a $350M share repurchase authorization increase.

$DLBMed

Why Dolby Labs Stock Popped Today

Dolby Laboratories (NYSE: DLB) shares rose 11.7% by 10:45 a.m. ET after its fiscal Q3 2026 results. The company reported revenue of $305 million versus an estimated $312 million, and EPS of $0.69 versus $0.67 expected. GAAP EPS was $0.30. Dolby guided Q4 sales to $362 million-$392 million and full-year revenue to at least $1.4 billion.

$DLBMedAI 8/10

Dolby (DLB) Q3 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Peter L. Goldmacher Chief Executive Officer - Kevin J. Yeaman Chief Financial Officer - Robert J. Park TAKEAWAYS Revenue -- $305 million, falling within management guidance ranges despite timing-related impacts in foundational audio. Non-GAAP EPS -- $0.69, exceeding the midpoint of guidance as lower operating expenses helped offset revenue shifts.

$DLBMed

Dolby Laboratories (NYSE:DLB) Misses Q2 CY2026 Sales Expectations

Audio and video technology company Dolby Laboratories (NYSE: DLB) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 3.3% year on year to $305 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $377 million at the midpoint, or 7.4% above analysts’ estimates. Its non-GAAP profit of $0.69 per share was 3% above analysts’ consensus estimates. Is now the time to buy Dolby Laboratories?

$DLBHighAI 9/10

Dolby Laboratories Reports Third Quarter 2026 Financial Results

Copyright 2026 PR Newswire. All Rights Reserved 2026-07-30 SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE:DLB) today announced the company's financial results for the third quarter of fiscal 2026. "We continue to execute against our full-year objectives, and we are building momentum across several of our key growth areas," said Kevin Yeaman, President and CEO, Dolby Laboratories.

$DLBHigh

Dolby Laboratories, Inc. (DLB): Results of Operations and Financial Condition

Dolby Laboratories, Inc. (DLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d165402dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dolby Laboratories Reports Third Quarter 2026 Financial Results SAN FRANCISCO, July 30, 2026 — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the third quarter of fiscal 2026. “We co